Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

CAMP vs OMER: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

OMER Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 8–2 Matrix Metrics)

OMER Overall Winner 6-Pillar Tally: CAMP 2 – 3 OMER (1 Tie) Matrix Metrics: CAMP 2 – 8 OMER

As of Nov 17, 2026, Omeros Corporation (OMER) is the stronger overall head-to-head candidate over CAMP4 Therapeutics Corporation (CAMP) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CAMP carries a Unified Composite Score of 43.9/100 (HOLD) at $3.95 (N/M Forward P/E, -991.8% operating margin), whereas OMER carries 50.8/100 (HOLD) at $13.70 (73.0x Forward P/E, -189.5% operating margin).

  • Growth vs. Quality Trade-Off: OMER earns the overall head-to-head edge with a stronger Unified Composite Score (50.8/100 HOLD vs. CAMP 43.9/100 HOLD) and 1.97β · 81% Vol risk profile, whereas CAMP leads top-line expansion (+138.9% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: CAMP trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 51.9); meanwhile OMER is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CAMP vs OMER
CAMP NASDAQ
CAMP4 Therapeutics Corporation Common Stock
Pharmaceutical Preparations
$3.95
+2.33% 1D
Market Cap $238.5M
TTM Revenue $5.3M
Forward P/E N/M
Beta / 30D Vol 1.34β · 94% Vol
Unified Composite Score
43.9 / 100 HOLD
Tech 34.0 Fund 40.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 52
RSI-14: 51.9 · SMA20: $3.82 · SMA50: $3.84
OMER NASDAQ Head-to-Head Winner
Omeros Corporation
Pharmaceutical Preparations
$13.70
-17.87% 1D
Market Cap $1.3B
TTM Revenue $27M
Forward P/E 73.0x
Beta / 30D Vol 1.97β · 81% Vol
Unified Composite Score
50.8 / 100 HOLD
Tech 33.0 Fund 52.0 Flow 70.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -1.6%), weak momentum, RSI 30
RSI-14: 30.3 · SMA20: $17.29 · SMA50: $18.11

6-Pillar Scorecard Institutional Category Breakdown (CAMP 2 – 3 OMER)

Columns: Metric · CAMP · OMER
1. Valuation Multiples OMER
Forward P/E N/M 73.0x
Trailing P/E N/M 14.3x
PEG Ratio N/M 0.81x
EV / Revenue 26.6x 50.1x
2. Growth & Scale OMER
Revenue Growth (YoY) +138.9% +14.9%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $5.3M $27M
Market Cap $238.5M $1.3B
3. Profitability & Quality OMER
Gross Margin N/A 38.3%
Operating Margin -991.8% -189.5%
Net Profit Margin 0.0% 324.9%
Return on Equity (ROE) -146.1% -576.3%
4. Balance Sheet & Cash Flow CAMP
Cash Generation (TTM) -$26M -$49M
Cash Flow Margin N/A N/A
Net Cash / Leverage $97M Net Cash $97M Net Debt
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CAMP
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) 85.5% (28th %ile)
Put/Call OI Skew N/A 0.18x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CAMP (2) vs OMER (8)
Institutional Metric CAMP OMER Criterion Row Edge
Market Capitalization
Scale
$238.5M $1.3B Larger Scale OMER
Trailing P/E Ratio
Valuation
N/M 14.3x Lower Multiple OMER
Forward P/E Ratio
Valuation
N/M 73.0x Lower Multiple OMER
Revenue Growth (YoY)
Growth
+138.9% +14.9% Higher Growth CAMP
Operating Margin (TTM)
Profitability
-991.8% -189.5% Higher Margin OMER
Net Profit Margin
Profitability
0.0% 324.9% Higher Margin OMER
Return on Equity (ROE)
Capital Efficiency
-146.1% -576.3% Higher ROE CAMP
52-Week Range Position
Momentum
22% ($3–$8) 48% ($7–$21) Stronger Trend OMER
Beta / 30D Volatility
Risk Regime
1.34β · 94% Vol 1.97β · 81% Vol Lower Realized Risk OMER
Unified Institutional Score
Composite Signal
43.9 / 100 (HOLD) 50.8 / 100 (HOLD) Higher Composite OMER
Trailing 12M Revenue (USD)
Operating Scale
$5.3M $27M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 38.3% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 26.6x EV/Rev 0.81x PEG · 50.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$26M ($97M Net Cash) -$49M ($97M Net Debt) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CAMP +42.01 pp
CAMP: +25.8% · OMER: -16.21%
3M Horizon CAMP +10.45 pp
CAMP: -15.05% · OMER: -25.5%
6M Horizon OMER +19.27 pp
CAMP: -4.82% · OMER: +14.45%
1Y Horizon OMER +77.74 pp
CAMP: -3.66% · OMER: +74.08%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period CAMP Revenue OMER Revenue CAMP Op. Margin OMER Op. Margin Margin Leader
FY2016 N/A $40M N/A -130.4% OMER
FY2017 N/A $60M N/A -67.7% OMER
FY2018 N/A $30M N/A -375.7% OMER
FY2019 N/A $110M N/A -130.6% OMER
FY2020 N/A $70M N/A -212.6% OMER
FY2023 $0M N/A -14822.6% N/A CAMP
FY2024 $0M N/A -8142.3% N/A CAMP
FY2025 $0M N/A -1502.4% N/A CAMP

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CAMP UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CAMP Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
OMER BREAKDOWN
40d in phase · OBV DISTRIBUTION
Current IV 85.5%
IV Percentile 28th %ile
Put/Call OI Skew 0.18x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact OMER Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $16.68 · IV 90.2%

OMER Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($1,668)

Compare $1,668 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 90.2% ATM IV.

5-DAY BULLISH SWING Liq A

Dec 18 $18 / $20 Bull Call Spread

Buy 3x $18C · Sell 3x $20C · 32d

Net Entry $285 Debit
T+5d @ +5% Move +$22 (+8%)
Max Risk / Buffer $285 Capped
5d Edge & Liquidity 0.4x R:R · Liq A
Simulate 5-Day Payoff →
5-DAY DOWNSIDE SPREAD Liq C

Dec 18 $18 / $15 Bear Put Spread

Buy 1x $18P · Sell 1x $15P · 32d

Net Entry $198 Debit
T+5d @ -5% Drop +$19 (+10%)
Max Risk / Buffer $198 Capped
5d Edge & Liquidity 0.5x R:R · Liq C
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CAMP Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $238.5M market capitalization and -991.8% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
OMER Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.3B market capitalization and -189.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CAMP vs OMER Key Questions & Quantitative Answers

As of Nov 17, 2026, Omeros Corporation (OMER) is the stronger overall head-to-head candidate over CAMP4 Therapeutics Corporation (CAMP) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CAMP carries a Unified Composite Score of 43.9/100 (HOLD) at $3.95 (N/M Forward P/E, -991.8% operating margin), whereas OMER carries 50.8/100 (HOLD) at $13.70 (73.0x Forward P/E, -189.5% operating margin). Growth vs. Quality Trade-Off: OMER earns the overall head-to-head edge with a stronger Unified Composite Score (50.8/100 HOLD vs. CAMP 43.9/100 HOLD) and 1.97β · 81% Vol risk profile, whereas CAMP leads top-line expansion (+138.9% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: CAMP trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 51.9); meanwhile OMER is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

OMER leads the Growth & Scale pillar: CAMP posts +138.9% YoY revenue growth and +0.0% YoY earnings growth on $5.3M TTM revenue (N/A gross margin, -991.8% operating margin), compared with OMER at +14.9% YoY revenue growth and +0.0% YoY earnings growth on $27M TTM revenue (38.3% gross margin, -189.5% operating margin). Across the 8-period historical trajectory (FY2016 to FY2025), CAMP cumulative revenue shifted N/A while OMER shifted +75.0%. In operating R&D and SG&A reinvestment, CAMP deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for OMER.

OMER screens cheaper on headline valuation multiples. CAMP trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 26.6x EV/Revenue (unreported FCF margin), whereas OMER trades at 73.0x Forward P/E, 14.3x Trailing P/E, 0.81x PEG, and 50.1x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CAMP (-146.1% ROE) versus OMER (-576.3% ROE) capital efficiency.

In options market volatility and institutional positioning, CAMP carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.34β · 94% Vol realized risk). By comparison, OMER carries 85.5% implied volatility (28th %ile, Balanced (25th–60th %ile)), a 0.18x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.97β · 81% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.